The Experts below are selected from a list of 75 Experts worldwide ranked by ideXlab platform
Mariusz Tomaniak - One of the best experts on this subject based on the ideXlab platform.
-
the ultra thin Strut sirolimus eluting coronary stent supraflex
Future Cardiology, 2021Co-Authors: Chao Gao, Rodrigo Modolo, Kuniaki Takahashi, Norihiro Kogame, Rutao Wang, Hideyuki Kawashima, Masafumi Ono, Hironori Hara, Mariusz TomaniakAbstract:Percutaneous coronary interventions with drug-eluting stents is currently the preferred revascularization treatment strategy for coronary artery disease. Following the first generation, the second-generation drug-eluting stents was designed with a Thinner Strut, better biocompatible polymer with/without bioresorbable coating or even polymer-free Struts. The SUPRAFLEX stent system has ultra-thin Struts (60 μm) across all stent diameters and a biodegradable polymer coating, enabling 70% of the sirolimus elution within 7 days. SUPRAFLEX has been assessed in large scale randomized controlled trials. This review summarizes the design of the SUPRAFLEX stent, the results of the pivotal clinical trials and outlines the ongoing research programs.
Rodrigo Modolo - One of the best experts on this subject based on the ideXlab platform.
-
the ultra thin Strut sirolimus eluting coronary stent supraflex
Future Cardiology, 2021Co-Authors: Chao Gao, Rodrigo Modolo, Kuniaki Takahashi, Norihiro Kogame, Rutao Wang, Hideyuki Kawashima, Masafumi Ono, Hironori Hara, Mariusz TomaniakAbstract:Percutaneous coronary interventions with drug-eluting stents is currently the preferred revascularization treatment strategy for coronary artery disease. Following the first generation, the second-generation drug-eluting stents was designed with a Thinner Strut, better biocompatible polymer with/without bioresorbable coating or even polymer-free Struts. The SUPRAFLEX stent system has ultra-thin Struts (60 μm) across all stent diameters and a biodegradable polymer coating, enabling 70% of the sirolimus elution within 7 days. SUPRAFLEX has been assessed in large scale randomized controlled trials. This review summarizes the design of the SUPRAFLEX stent, the results of the pivotal clinical trials and outlines the ongoing research programs.
Chao Gao - One of the best experts on this subject based on the ideXlab platform.
-
the ultra thin Strut sirolimus eluting coronary stent supraflex
Future Cardiology, 2021Co-Authors: Chao Gao, Rodrigo Modolo, Kuniaki Takahashi, Norihiro Kogame, Rutao Wang, Hideyuki Kawashima, Masafumi Ono, Hironori Hara, Mariusz TomaniakAbstract:Percutaneous coronary interventions with drug-eluting stents is currently the preferred revascularization treatment strategy for coronary artery disease. Following the first generation, the second-generation drug-eluting stents was designed with a Thinner Strut, better biocompatible polymer with/without bioresorbable coating or even polymer-free Struts. The SUPRAFLEX stent system has ultra-thin Struts (60 μm) across all stent diameters and a biodegradable polymer coating, enabling 70% of the sirolimus elution within 7 days. SUPRAFLEX has been assessed in large scale randomized controlled trials. This review summarizes the design of the SUPRAFLEX stent, the results of the pivotal clinical trials and outlines the ongoing research programs.
Louis Cannon - One of the best experts on this subject based on the ideXlab platform.
-
a prospective evaluation of the safety and efficacy of the taxus element paclitaxel eluting coronary stent system for the treatment of de novo coronary artery lesions design and statistical methods of the perseus clinical program
Trials, 2010Co-Authors: Dominic J Allocco, Scott Wehrenberg, Amy Britt, Andrey Nersesov, Louis Cannon, Keith D Dawkins, John Heil, Dean J KereiakesAbstract:Paclitaxel-eluting stents decrease angiographic and clinical restenosis following percutaneous coronary intervention compared to bare metal stents. TAXUS Element is a third-generation paclitaxel-eluting stent which incorporates a novel, Thinner-Strut, platinum-enriched metal alloy platform. The stent is intended to have enhanced radiopacity and improved deliverability compared to other paclitaxel-eluting stents. The safety and efficacy of the TAXUS Element stent are being evaluated in the pivotal PERSEUS clinical trials. The PERSEUS trials include two parallel studies of the TAXUS Element stent in single, de novo coronary atherosclerotic lesions. The PERSEUS Workhorse study is a prospective, randomized (3:1), single-blind, non-inferiority trial in subjects with lesion length ≤28 mm and vessel diameter ≥2.75 mm to ≤4.0 mm which compares TAXUS Element to the TAXUS Express2 paclitaxel-eluting stent system. The Workhorse study employs a novel Bayesian statistical approach that uses prior information to limit the number of study subjects exposed to the investigational device and thus provide a safer and more efficient analysis of the TAXUS Element stent. PERSEUS Small Vessel is a prospective, single-arm, superiority trial in subjects with lesion length ≤20 mm and vessel diameter ≥2.25 mm to <2.75 mm that compares TAXUS Element with a matched historical bare metal Express stent control. The TAXUS PERSEUS clinical trial program uses a novel statistical approach to evaluate whether design and metal alloy iterations in the TAXUS Element stent platform provide comparable safety and improved procedural performance compared to the previous generation Express stent. PERSEUS trial enrollment is complete and primary endpoint data are expected in 2010. PERSEUS Workhorse and Small Vessel are registered at http://www.clinicaltrials.gov , identification numbers NCT00484315 and NCT00489541.
-
a prospective evaluation of the safety and efficacy of the taxus element paclitaxel eluting coronary stent system for the treatment of de novo coronary artery lesions design and statistical methods of the perseus clinical program
Trials, 2010Co-Authors: Dominic J Allocco, Scott Wehrenberg, Amy Britt, John E Heil, Andrey Nersesov, Louis Cannon, Keith D Dawkins, Dean J KereiakesAbstract:Background Paclitaxel-eluting stents decrease angiographic and clinical restenosis following percutaneous coronary intervention compared to bare metal stents. TAXUS Element is a third-generation paclitaxel-eluting stent which incorporates a novel, Thinner-Strut, platinum-enriched metal alloy platform. The stent is intended to have enhanced radiopacity and improved deliverability compared to other paclitaxel-eluting stents. The safety and efficacy of the TAXUS Element stent are being evaluated in the pivotal PERSEUS clinical trials.
-
reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin Strut taxus liberte stent 1 year results from the taxus atlas program
Jacc-cardiovascular Interventions, 2008Co-Authors: Mark Turco, Jack J. Hall, Gregory Mishkel, Charles Oshaughnessy, Tift Mann, Louis Cannon, John A Ormiston, Mark Webster, Thomas F McgarryAbstract:Objectives The TAXUS ATLAS Small Vessel (SV) and Long Lesion (LL) multicenter studies compared the performance of the thin-Strut (0.0038 inch) TAXUS Liberte 2.25-mm stent (Boston Scientific; Natick, Massachusetts) and the TAXUS Liberte 38-mm long stent (Boston Scientific; Natick, Massachusetts) with the earlier paclitaxel-eluting TAXUS Express (Boston Scientific) stent that has identical polymer, drug dosage, and release kinetics but different stent geometry and thicker Struts (0.0052 inch). Background The TAXUS Liberte stent was designed with Thinner and more even Strut spacing to provide more uniform drug distribution, as well as increased flexibility and conformability. Clinical benefits of the new stent design have not been evaluated. Methods The TAXUS ATLAS SV and LL studies are nonrandomized studies comparing outcomes of the TAXUS Liberte 2.25 mm (N = 261) and TAXUS Liberte 38 mm (N = 150) stents to TAXUS Express historical control groups derived from the TAXUS IV and V trials. Inclusion/exclusion criteria for TAXUS Express and Liberte groups were similar in both studies. Results Each study met its primary end point of noninferiority of 9-month in-segment diameter stenosis. Furthermore, TAXUS Liberte 2.25 mm, when compared with TAXUS Express, significantly reduced the rate of both 9-month angiographic restenosis (18.5% vs. 32.7%, p = 0.0219) and 12-month target lesion revascularization (6.1% vs. 16.9%, p = 0.0039). In addition, TAXUS Liberte 38 mm significantly reduced the risk of 12-month myocardial infarction compared with TAXUS Express (1.4% vs. 6.5%, p = 0.0246). Conclusions The Thinner-Strut TAXUS Liberte stent improved outcomes compared with the earlier TAXUS Express stent in both SVs and LLs (A Study of the TAXUS Liberte Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels; NCT00371748 ; A Study of the TAXUS Liberte Stent for the Treatment of Long De Novo Coronary Artery Lesions; NCT00371475 ).
Albert Schömig - One of the best experts on this subject based on the ideXlab platform.
-
Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial
Journal of the American College of Cardiology, 2003Co-Authors: Adnan Kastrati, Julinda Mehilli, Josef Dirschinger, Franz Dotzer, Helmut Schühlen, Franz-josef Neumann, Martin Fleckenstein, Conrad Pfafferott, Melchior Seyfarth, Albert SchömigAbstract:Background—Increased thrombogenicity and smooth muscle cell proliferative response induced by the metal Struts compromise the advantages of coronary stenting. The objective of this randomized, multicenter study was to assess whether a reduced Strut thickness of coronary stents is associated with improved follow-up angiographic and clinical results. Methods and Results—A total of 651 patients with coronary lesions situated in native vessels .2.8 mm in diameter were randomly assigned to receive 1 of 2 commercially available stents of comparable design but different thickness: 326 patients to the thin-Strut stent (Strut thickness of 50 mm) and 325 patients to the thick-Strut stent (Strut thickness of 140 mm). The primary end point was the angiographic restenosis ($50% diameter stenosis at follow-up angiography). Secondary end points were the incidence of reinterventions due to restenosis-induced ischemia and the combined rate of death and myocardial infarctions at 1 year. The incidence of angiographic restenosis was 15.0% in the thin-Strut group and 25.8% in the thick-Strut group (relative risk, 0.58; 95% CI, 0.39 to 0.87; P50.003). Clinical restenosis was also significantly reduced, with a reintervention rate of 8.6% among thin-Strut patients and 13.8% among thick-Strut patients (relative risk, 0.62; 95% CI, 0.39 to 0.99; P50.03). No difference was observed in the combined 1-year rate of death and myocardial infarction. Conclusions—The use of a Thinner-Strut device is associated with a significant reduction of angiographic and clinical restenosis after coronary artery stenting. These findings may have relevant implications for the currently most widely used percutaneous coronary intervention. (Circulation. 2001;103:2816-2821.)